Chair: Ken-ichi Yoshida,＊ Programme ＊Director , Centre for EU Studies /Executive Director , Brussels European Centre /Kobe University

13:00 Opening Address

Hideki Fukuda , President of Kobe University

13:10 Introduction to JEUPISTE project

Toshiyasu Ichioka , EU-Japan Centre for Industrial Cooperation

13:30 European Bioeconomy - Bio-based Industries

Tom Kuczynski , The delegation of the European Union to Japan

14:00 International networking biobased chemical production in Asia
Chiaki Ogino , Kobe University

14:20 European bio-based chemical production

Florian David , Chalmers University of Technology , Sweden

14:50 Break（ Networking )15:20 Bio-lipid platform: fermentative and enzymatic lipid production
and transformation for future chemical industry
Jun Ogawa , Kyoto University

15:40 Fabrication and Bio-fabrication in Nanomedicine: The Spanish Research Center
in Bioengineering, Biomaterials and Nanomedicine
Esther Vazquez Gomez , CIBER-BBN , Spain

16:10 Towards a sustainable society: R&D Activities at Nagase
Xiaoli Liu , NAGASE CO., LTD

16:30 2G commercialization in Asia Paciﬁc

Bas Melssen , Novozymes Malaysia , Malaysia

Japan - Europe academic workshop for sharing ideas and experiences
towards strategic partnership building“Biobased Chemical production”
Toshiyasu Ichioka
Project manager
Institute for International Studies and Training /EU-Japan Centre for Industrial Cooperation

Toshiyasu ICHIOKA is responsible for the promotion of EU-Japan cooperation in innovation,science and technology at the EU-Japan Centre for Industrial Cooperation. Among others he ismanaging the project, Japan-EU Partnership in Innovation, Science and TEchnology (JEUPISTE),
co-ﬁnanced under FP7 (GA No. 609585). Activities include contribution to the EU-Japan STI
policy dialogues, organization of seminars and workshops, EU-Japan bilateral dissemination,and liaising with various stakeholders. Since November 2013, he has been the Japanese National Contact Point (NCP)
Coordinator for Horizon 2020.
Prior to joining the EU-Japan Centre for Industrial Cooperation, he had a career as project manager for FP6 eHealth project atUniversitat Pompeu Fabra (ES) and as researcher on experimental atomic physics at various research institutions: Marie Curie
Fellow at University of Latvia (LV), Max-Planck-Institute for Nuclear Physics (DE), Aarhus University (DK), CERN (CH) and RIKEN(JP). He holds a PhD and MSc in Multi-Disciplinary Sciences from University of Tokyo and a BSc in Physics from Kyoto University
(JP).

“

”

Abstract:
The Japan-EU Partnership in Innovation, Science and TEchnology, JEUPISTE, project is co-ﬁnanced under European Framework
Programme FP7, aiming at further enhancing the level of Japan-Europe cooperation in science, technology and innovation. In
this talk, the overall structure and activities of the project and rationale behind the organziation of the academic workshop will
be presented.
Horizon 2020, started in 2014 after FP7 and other European programmes, is the largest EU programme for research andinnovation in Europe. It is characterized with its openness and comprehensive nature. The almost all the programme is open toparticipation from countries outside Europe, as long as minimum conditions set for each call for applications are met. This does
not mean that Japanese participants will be eligible for automatic funding from the EC, but gives great opportunities forJapanese researchers and research organizations to collaborate with top-class European counterparts and share results.
The JEUPSITE project is promoting the Europe-Japan cooperation through Horizon 2020 and other relevant programmes. This
topical workshop is organized to help the community actively build partnership. Meaning of such strategic partnership will be
discussed.

Chiaki Ogino
Associate Professor, Department of Chemical Science and Engineering, Graduate School ofEngineering, Kobe University, Japan
Education:
1993.4 – 1995.3 Department of chemical engineering, Faculty of engineering, Kobe University
1995.4 – 1997.3 Department of chemical science and engineering, Graduate school of scienceand technology, Kobe University
1997.4 – 1999.7 Division of molecular science, Graduate school of science and technology, Kobe
University (Doctor course)
2001.3
Awarded the degree of Ph.D, Kobe University for thesis entitled “Characterization of phospholipase D (PLD)from Streptoverticillium cinnamoneum and its application for phospholipid synthesis”.
Research and Professional Experience:
1999.1 – 1999.7 JSPS Research Fellowships for Young Scientists (DC2)1999.8 – 2001.12 Assistant professor, Department of chemistry and chemical engineering, Kanazawa University
2002.1 – 2007.7 Assistant Professor, Division of Material Engineering, Graduate School of Natural Science and Technology,
Kanazawa University
2007.8 -Present Associate Professor, Department of Chemical Science and Engineering, Graduate School of Engineering, Kobe
University
Awards: 2007.3 Young research award for encouragement in Society of Chemical Engineers, Japan (SCEJ)
2010.9Young research award for encouragement in Society for Biotechnology, Japan (SBJ)
Research interests:
Yeast breeding for bio-reﬁnery
Ethanol fermentation from cellulosic material
Metabolic engineering in Streptomyces
Protein expression by fungi and Streptomyces
Application of AFM to bimolecular interaction assessment
Membership:Society of Chemical Engineering, Japan (1993 ~)Society for Biotechnology, Japan (1999 ~)Japan Society of Enzyme Engineering (2000 ~)Chemical Society of Japan (2003 ~)Society for Actinomycete Japan (2006 ~)Japan Society for Bioscience, Biotechnology, and Agrochemistry (2007 ~)“”Abstract:
There can be a number of natural not-yet-discovered microorganisms that enables us to overcome the problems in direct
fermentation of lignocellulosic biomass. However, natural isolates rather often require speciﬁc conditions for their cultivation,
which restricts us to select out the best performing candidate strains.
Strains of Saccharomyces cerevisiae are used traditionally for industrial production of ethanol, but most of ever -establishedstrains are susceptible to aforementioned inhibitors and other stress conditions related to lignocellulosic biomass conversion.
And thus some artiﬁcial strains tolerant to inhibitors, such as furfural and 5-HMF, have been developed based on the metabolicengineering strategy; however their performance is far from being ideal. Therefore, we focus on potential in the culturecollections in Asian countries, including Japan, Indonesia, Thailand, and Malaysia, since these collections are alreadyestablished resources of strains that could possess higher tolerance to the inhibitors.
We have developed a method to screen out candidate yeasts, which are simultaneously capable to grow well and ferment
lignocellulosic lysate into ethanol and ﬁne chemicals such as lactate. Applying the method to the Asian culture collections,
including National Bio-resource Collection (NBRC) Japan and Indonesian National Culture Collection (InaCC), the actual
screening was conducted to discover candidate strains with better growth and fermentation capacities even in the medium
containing the inhibitors. In this presentation, potential of Asian bio-resources for bio-reﬁnery will be also discussed.

Tom Kuczynski
The delegation of the European Union to Japan
Born in 1977 in Poland
Master of Finance and Banking, Cracow University of Economics, Poland completed in 2001
Doctor of Economics (corporate ﬁnance), Hiroshima Shudo University, Japan, completed in2006
From 2006 to 2012 working at the Embassy of the Republic of Poland in Japan (First Secretary)
covering Science, Technology and Innovation, Energy and Climate Change issues
Since 2012 working as a science advisor at the S&T section of the EU Delegation to Japan,
responsible for issues related to the research cooperation between the EU and Japan“”

Abstract:
European Bioeconomy - Bio-based Industries(Horizon 2020 and Joint Undertaking BBI)
Over the coming decades, the world will witness increased competition for limited and ﬁnite natural resources. A growing
global population will need a safe and secure food supply. Also, in the context of climate change, a transition is needed towards
an optimal use of renewable biological resources.
Bioeconomy – encompassing the sustainable production of renewable resources from land, ﬁsheries and aquaculture
environments and their conversion into food, feed, ﬁber bio-based products and bio-energy as well as the related public goods– is an important element of Europe’s reply to the challenges ahead. Bioeconomy includes primary production, such as
agriculture, forestry, ﬁsheries and aquaculture, and industries using / processing biological resources, such as the food and pulp
and paper industries and parts of the chemical, biotechnological and energy industries. Bioeconomy represents a market
estimated to be worth over EUR 2 trillion, providing 20 million jobs and accounting for 9 % of total employment in the EU in2009.
EU-level Bioeconomy related research and innovation is carried out under Horizon 2020, EU's new framework programme forresearch and innovation, through the activities of the Bio-Based Industries Joint Undertaking and other initiatives andinstruments.
Horizon 2020 is the new EU framework programme for R&I running from 2014 to 2020 with the biggest ever budget of nearly
EUR 80 billion. Research on Bioeconomy in H2020 is carried out mostly under, Societal Challenge 2 'Food security, sustainableagriculture and forestry, marine and maritime and inland water research and the bioeconomy' and the Key Enabling
Technologies 'Biotechnology' programme. Every euro invested in Bioeconomy research and innovation under Horizon 2020 is
expected to generate about 10 EUR in value added. It will also contribute to the Commission's Europe 2020 goal on moving to a
low-carbon economy by 2050.
The European Institute of Technology with its Knowledge and Innovation Communities (funded under Horizon 2020) also
contributes to the advancement of the broadly deﬁned Bioeconomy in Europe.
The Bio-Based Industries Joint Undertaking (JU BBI) is a new EUR 3.7 billion Public-Private Partnership between the EU and the
Bio-based Industries Consortium aiming at increasing investment in the development of a sustainable bio-based industry sectorin Europe. EUR 975 million of its budget (26%) comes from Horizon 2020 and leverages EUR 2.7 billion of private investment(74%). It aims at providing environmental and socio-economic beneﬁts for European citizens, increasing the competitiveness ofEurope and contributing to establishing Europe as a key player in research, demonstration and deployment of advanced biobased products and biofuels. The JU BBI will play an important role in developing European Bioeconomy, reducing Europe’s
dependency on fossil-based products, helping the EU meet climate change targets, and leading to greener and moreenvironmentally friendly growth. The key is to develop new bioreﬁning technologies to sustainably transform renewable
natural resources into bio-based products, materials and fuels. Currently, the private partner of BBI called BIC (Biobased
Industries Consortium) has 77 full members (large industries, SMEs and clusters) and 137 associate members (universities,
research institutes, associations, European Technology Platforms and one bank). BBI calls are open to all participants (includinginternational partners), following the general rules of Horizon 2020 i.e. openness, transparency and excellence.
Research and Innovation in bioeconomy is carried out also under other initiatives. Smart specialisation is a new innovation
policy concept designed to promote the eﬃcient and eﬀective use of public investment in research, through funds dedicated toEuropean regional policy. Its goal is to boost regional innovation in order to achieve economic growth and prosperity, byenabling regions to focus on their strengths.
Furthermore, Horizon 2020 provides matching funding to the European Innovation Partnerships in the three areas:'Agricultural Productivity and Sustainability', 'Water' and 'Raw Materials'.
Finally, many EU Member States have developed and actively pursue national bioeconomy R&I programmes, which arecomplimentary to the EU initiatives.

Horizon 2020 is open to the whole world and Japanese participation is welcomed in all Calls for Proposals. Current calls related
to bioeconomy/bioindustries:• Converting CO2 into chemicals (deadline 1st stage: 14 Feb 2015)
http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/calls/h2020-isib-2015-1.html• The next H2020 calls in bioeconomy (for 2016-17) are expected to be published in autumn 2015, and the next call of BBI (for2015) in spring 2015. For more details, see Participant Portal
http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/index.html
Contact: tom.kuczynski@eeas.europa.eu
1EIPs are a new approach to EU research and innovation, challenge-driven, focusing on societal benefits and a rapid
modernisation of the associated sectors and markets. EIPs act across the whole research and innovation chain,bringing together all relevant actors at EU, national and regional levels in order to: (i) step up research anddevelopment efforts; (ii) coordinate investments in demonstration and pilots; (iii) anticipate and fast-track any
necessary regulation and standards; and (iv) mobilise ‘demand’ in particular through better coordinated public
procurement to ensure that any breakthroughs are quickly brought to market. Rather than taking the above steps
independently, as is currently the case, the aim of the EIPs is to design and implement them in parallel to cut leadtimes. EIPs are launched only in areas, and consist only of activities, in which government intervention is clearlyjustified and where combining EU, national and regional efforts in R&D and demand-side measures will achieve thetarget quicker and more efficiently. http://ec.europa.eu/research/innovation-union/index_en.cfm?pg=eip

Florian David
Systems & Synthetic Biology Group, Department of Biology and Biological Engineering,
Chalmers University of Technology, Sweden
e-mail:davidﬂ@chalmers.de
General Information
Date of birth: 1981, Braunschweig, Germany Citizenship: German
Education and Degrees
2007 Diploma (M.Sc.) in Biotechnology, Technische Universitat (TU) Braunschweig, Germany
2011 Ph.D. in Biotechnology, Institute of Biochemical Engineering, TU Braunschweig, Germany
2011 Engineering Degree, Faculty of Mechanical Engineering, TU Braunschweig, Germany

Positions
2003-2005 Research assistant at the Department of Cell and Molecular Biology, TU Braunschweig
2007-2011 PhD student, Institute of Biochemical Engineering, TU Braunschweig, Germany
2011-2013 Post doc at the Collaborative Research Center SFB578, Institute of Biochemical Engineering, Prof. Christoph
Wittmann, TU Braunschweig, Germany
March2013Post doc at the Department of Chemical and Biological Engineering, Prof. Jens Nielsen, Chalmers University ofTechnology, Goteborg, Sweden
Feb2014 Cofounder and Director of Biopetrolia AB
Awards and Honors
2007
Biotechnica Award for best Diploma in Biotechnology of the year in Germany
2011
BluesenscCompetition Award, 2nd place (worldwide competition for optimizing gas analysis in bioprocesses)
Management Experience
2007-2009 Public relation work – organization of Public Open Days, courses for school children
2008
Writing a research proposal (SFB578, TPB8) which was approved for funding from the Deutsche
Forschungsgemeinschaft (DFG)
2008-2012 Coordinator of the subproject B8 as part of the Collaborative Research Center SFB578; Close collaborations withdepartments at the TU Braunschweig, MPI Magdeburg, Fraunhofer (ITEM), Germany; Axetris/Leister company,
Switzerland
2008-2012 Bioreactor and Flow Cytometer facility management
2014-2015 Cofounder of Biopetrolia AB,Director -acquiring seed funding, business plan development
Teaching
Organizing and teaching 2 practical student courses and 2 lectures for master students in the ﬁeld of Advanced Biochemical
Engineering and Biotechnology.
Mentoring
Publications & Presentations
Supervision of Bachelor Students
7
Peer reviewed publications
16
Supervision of Master Students
4
Conference Contributions
18
Supervision of PhD Students/Postdocs
4(10 posters, 8 oral presentations)“”

Abstract:
Implementing bio-based chemical production has three main challenges:Developing biotechnology itself, restructure industrial
and economic systems and raising social awareness and acceptance. In these ﬁelds Europe developed special funding programs
and created infrastructures for interdisciplinary and international research visioning a biosustainable future. Interdisciplinary
research happens on various levels ranging from projects within universities, national research centers to internationalframework programs. Among them Horizon 2020 is a new European program, which involves both academia and industry to
combine research and innovation activities on a multinational level, aiming for the translation of knowledge into marketableproducts and services. The development of eﬃcient cell factories is fundamental for establishing such a biosustainableeconomy. Fine chemical production by microorganisms is increasingly reliant on tools derived from metabolic engineering andsynthetic biology. The use of high throughput techniques and automation for the design of these cell factories, especially
platform strains, is playing an important role in the transition from laboratory research to industrial production. Modelorganisms such as Saccharomyces cerevisiae and Escherichia coli are widely used as host strains due to their robust anddesirable traits. Academia and industry have in many cases joined forces where we are starting to see the fruits of these joint
ventures in products that have reached the market and are now seen in our food, pharmaceuticals and fuels.

Jun Ogawa
Professor, Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University,
Japan
Educa on Background:
1990
Bachelor of Science, Department of Agricultural Chemistry, Kyoto University, Japan
1992
MS (Master of Science), Department of Agricultural Chemistry, Kyoto University
1995
Ph.D. (Doctor of Agriculture), Kyoto University

Work Carrier:
1994~1995
Research fellow of Japan Society for Promo on of Science
1995~
Assistant Professor, Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University,Japan
2006, Aug~
Visi ng Researcher of INRA, France
2007, Feb
(Unité de Géné que Microbienne, L’Ins tut Na onal de la Recherche Agronomique)2008, Oct~
Professor, Research Division of Microbial Sciences, Kyoto University, Japan
2009, Oct~
Professor, Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Japan
Research Field:
Applied microbiology, Microbial biochemistry, Microbial physiology, Fermenta on physiology, Enzyme engineering,
Environmental microbiology, Microbial molecular biology.

“”

Abstract:
Fermenta ve and enzyme-catalyzed bioprocesses are promising for future environmental friendly industries and sustainable
socie s using biomass as energy and material sources.
Lipid fermenta on is promising to replace petroleum-derived highly reduced chemical materials by biomass derived ones. Biolipid fermenta on development through chemical mutant- and molecular-breeding of an oleaginous ﬁlamentous fungus
Mortierella alpina 1S-41,2) and bio-lipid transforma on by anaerobic bacteria will be discussed as new technologies for food andchemical industry2,3).
To make wider the use of bio-lipid derived chemicals, it is important to diversify available lipid-transforming reac ons by
developing mul -component enz
processes, which are func onal combina on of enz
eac ons and complex
biological systems providing energy or reducing power for the reac on. As examples, hydratase3,4), monooxygenase5),
dioxygenase6), and aldolase7) will be discussed.
1.Sakuradani, E. et al, J. Biosci. Bioeng., 116, 417-422 (2013).
2.Ogawa, J. et al, Eur. J. Lipid Sci. Technol., 114, 1107-1113 (2012).
3.Kishino, S. et al, Proc. Natl. Acad. Sci. USA, 110, 17808-17813 (2013).
4.Takeuchi, M. et al, Eur. J. Lipid Sci. Technol.,115, 386-393 (2013).
5.Sulistyaningdyah, W.T., et al., Appl.Microbiol. Biotechnol., 67, 556-562 (2005).
6.Hibi, M., et al., Appl. Microbiol. Biotechnol., 97, 2467-2472 (2013).
7.Horinouchi, N., et al., Microbial Cell Factories, 11, 82 (2012).

Esther Vazquez Gomez

1 Senior Researcher. Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona,
Bellaterra, 08193 Barcelona, Spain
2 Associate Professor.Department de Genètica i de Microbiologia, Universitat Autònoma de Barcelona,
Bellaterra, 08193 Barcelona, Spain
3 Member of the CIBER en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Bellaterra,
08193 Barcelona, Spain.
e-mail: esther.vazquez@uab.es
Previous positions:
1. Predoctoral fellowship holder. Universidad de Oviedo. 1993.
2. Predoctoral fellowship holder. Universidad de Valladolid. 1994-1996.
3. Assistant professor. Universidad de Valladolid. 1996-1997.
4. Postdoctoral researcher. Universidad de Valladolid. 1997-1999
5. Associated professor. Universitat Pompeu Fabra. 1999
6. Visiting professor. Universitat Pompeu Fabra. 1999-2000
7. Assistant professor. Universitat Pompeu Fabra. 2000-2003
8. Lecturer. Universitat Pompeu Fabra. 2004-2007
Academic background:
1. Master in Molecular Biology. 1992. State University of New York. USA.
2. Degree in Medicine. 1993. University of Valladolid, Spain.
3. PhD in Medicine. 1996. University of Valladolid, Spain. Special doctorate award.
Research interests:
Protein drug design, recombinant protein production, nanobiotechnology, self-assembling of protein-based nanoparticles for
drug delivery, gene therapy, regenerative medicine, cáncer, innovative research in protein production and aggregation.

“”

Abstract:
The Nanobiotechnology Research Unit belongs to the Biomedical Research Networking Center in Bioengineering, Biomaterials
and Nanomedicine (CIBER-BBN), one of nine CIBER consortia in Spain, created to promote research excellence and build acritical mass of researchers in the ﬁeld of Biomedicine and Health Sciences. The research programs of the CIBER-BBN are:
Bioengineering and biomedical imaging, Biomaterials and tissue engineering and Nanomedicine, stressing as an overall main
objective the enhancement of the research capabilities of the member groups by sharing resources, coordination andpromotion of synergies. Apart from the scientiﬁc programs, the CIBER-BBN has several cross programs; one of them, thePlatform of Production of Biomolecules, supply customized design and production of recombinant proteins, antibodies andsynthetic peptides needed to the development of research projects framed in the strategic lines of Tissue Engineering,Intelligent Devices, Implants, and specially Therapeutic Nanoconjugates and Biosensors. Inside this cross program the
Nanobiotechnology Research Unit serves as Protein Production Platform to other groups and institutions in a collaborative
framework or as a service, to design, produce and purify recombinant proteins as well as to optimize protocols. This platform
also oﬀers formation courses and counseling to their users.
The Nanobiotechnology Research Unit is also part of the Institute of Biotechnology and Biomedicine, located at the University
Autonoma of Barcelona, where we combine research and education. Our experience in recombinant protein production in
diﬀerent biological systems is complemented by the synergistic collaboration with other groups from the Institute and the
University, to perform a rational protein design towards the generation of complex and functional protein materials.
In this context, the Nanobiotechnology Unit enjoys an optimal environment to develop its research activity moving between
biotechnology, biomaterials and nanomedicine, to modify and create proteins for therapeutic uses. On one hand, we design
multidomain protein vehicles for a targeted drug delivery and therapies to improve the speciﬁcity and diminish the toxicity of
quimiotherapy agents in diﬀerent tumor models. These studies are performed in collaboration with diﬀerent CIBER -BBN
hospitals. In this research line, we have developed a new architectonic principle based on speciﬁc protein domains to promote
protein self-assembling as nanoparticles of regulatable size. These are addressed to reach an optimal cell internalization andbiodistribution, but also empowered with multivalent domains for speciﬁc targeting. On the other hand, we have developed a
new technology platform on the use of inclusion bodies as active biomaterials to be used as therapeutic nanopills for protein
replacement therapies or as slow protein delivery agents in regenerative medicine. They have been also explored as
topographical modiﬁers that favors mammalian cell adhesion, proliferation and diﬀerentiation in tissue engineering.

Xiaoli Liu
PhD, NAGASE CO., LTD, Japan
Educations
1982-1986
1990-1993

Employments
April, 2013-present:
Oct., 1993-March, 2013:
Sep., 1986-Nov., 1988:

B.Sc. University of Eastern China University of Chemical Engineering(Shanghai, P.R.China) Majored in Biochemistry
PhD. La Trobe University (Victoria, Australia) Majored in Biochemistry andmolecular biology

Nagase & Co., Ltd.
Position: Division Manager, Research & Development Center
Nagase ChemteX Corporation,
Position: General Manager, Enzyme Division
Institute of Microbiology, the Chinese Academy of Sciences
Position: Researcher

Major Publications:○Method for hydrolysis and base exchange of phospholipids, A. Daisuke & X. L. Liu, Japanese Patent 4678488, 2011
○Method for preparing a phospholipid composition, M. Shiihara, N. Taniwaki, X. L. Liu, Japanese Patent 4887674, 2011
○Method of removing enzyme and method of base exchange or hydrolysis of phospholipid using the same, X. L. Liu and N.
Taniwaki, Japanese Patent 4650746, 2010
○Physiological eﬀects of dietary PIPS soybean-derived phospholipid in Obese Zucker (fa/fa) rats, B, Shirouchi, K. Nagao, K.
Furuya, M. Shiojiri, X.L. Liu and T. Yanagita, Biosci. Biotechnol. Biochem., 74(11), 2333-2335, 2010
○GMO and Protein Engineering, Xiaoli Liu, Enzymes in Food technology, 2009:18 - 41, Robert j Whitehurst & Maarten Van Oort
○Cloning, sequencing and expression of the gene encoding NADH oxidase from the extreme anaerobic thermophile
Thermoanaerobium brokii , XL Liu and RK Scopes, Biochim Biophys Acta , Aug 1993; 1174(2): 187- 90“”

Abstract:
Nagase was founded in 1832 as a dyestuﬀ wholesale business entity in handling of natural dyes extracted from saﬄower andglue plant, as well as starch. Now the company has grown into a Globally-active Corporation and its activities are far beyond
trading. Nagase owns aﬃliated companies where chemicals, enzymes, functional sugars and pharmaceutical intermediates are
manufactured and supplied to various industries. Furthermore, it has its own Research and Development Center. Started withhandling natural products and thrived with the chemical industry, Nagase is now trying to achieve sustainable growth. One of
the key words for sustainability is eco-friendliness. Here, I would like to introduce the mission and activities of Nagase R&D indeveloping eco-conscious products and processes.

Bas Melssen
Head of Biomass Conversion - Asia Paciﬁc, Novozymes Malaysia Sdn Bhd
Bas has been living and working in Malaysia and throughout the region since 1997 and is a
Permanent Resident in Malaysia. He has a State Degree in Business Administration and an
Associate Degree in Business & Commerce from The Netherlands.
His background is in strategy consulting and business development. Before joining Novozymes
as the Head of ‘Biomass Conversion Business Development – Asia Paciﬁc’ this year, Bas worked
in the Special Innovation Unit in the Malaysian Prime Minister's Oﬃce for four years where hehas been responsible for conceptualizing and developing Malaysia’s National Biomass Strategy
2020 and other High-Impact economic programs. Prior to that he was Global Commercial Director for an Australian company
and headed up the Malaysian oﬃce for a Global consulting ﬁrm.
Internationally he has established commercial ventures throughout Asia Paciﬁc, Europe and the Middle East and has been aregular speaker at Biomass and Biofuels conferences around the world.

“”

Abstract:
Novozymes is the global leader in enzyme solutions and Bio Innovation. The company has been at the forefront of cellulosic
conversion to 2G BioFuels and BioChemicals.
With 5 commercial scale 2G ethanol plants operational around the world, the industry seems to have decided that enzymatichydrolysis is the most viable technology.
There’s a growing demand for ethanol in Asia Paciﬁc and by 2020 the region will likely run out of capacity to supply itself.
Chemicals derived from ethanol have been produced for decades and can now be produced from 2G Ethanol.
Plenty reasons for biomass owners, ethanol oﬀ-takers and downstream investors alike to secure the biomass supply chain forbiofuels and chemicals in Asia Paciﬁc region, as those who join in late will have to pay higher mobilization cost for the biomass.